keyword
MENU ▼
Read by QxMD icon Read
search

Hepatitis C genotype 3

keyword
https://www.readbyqxmd.com/read/28733564/the-clinical-features-and-treatment-outcome-of-chronic-hepatitis-c-with-pegylated-interferon-and-ribavirin-in-routine-care
#1
S S Tan, Z Adlin Nadia
AIM: To describe the clinical characteristic of hepatitis C (HCV) patients and the results of pegylated interferon and ribavirin (PegIFN/RBV) therapy in a routine clinical practice. METHODS: A retrospective review of consecutive HCV patients treated with PegIFN/RBV in 2004 to 2012. RESULTS: A total of 273 patients received treatment. The mean age was 44.16 ± 10.5 years and 76% were male. The top 2 self-reported risks were blood or blood product transfusion before 1994 and injection drug use, found in 57...
June 2017: Medical Journal of Malaysia
https://www.readbyqxmd.com/read/28730994/baseline-and-post-treatment-hepatitis-c-ns5a-resistance-in-relapsed-patients-from-a-multicentric-real-life-cohort
#2
Philippe Halfon, Caroline Scholtès, Jacques Izopet, Sylvie Larrat, Pascale Trimoulet, Fabien Zoulim, Laurent Alric, Sophie Métivier, Vincent Leroy, Denis Ouzan, Victor de Lédinghen, Sofiane Mohamed, Guillaume Pénaranda, Hacène Khiri, Marie-Ange Thélu, Anne Plauzolles, Laurent Chiche, Marc Bourlière, Florence Abravanel
BACKGROUND: Recent data have suggested that failure to achieve sustained virological response with direct-acting antiviral therapy is usually due to relapse and is primarily associated with the emergence of resistance-associated substitutions. The aim of this study was to investigate the prevalence and characterization of non-structural-5A resistance-associated substitutions in patients infected with hepatitis C virus genotypes 1, 3, and 4 treated by direct-acting antiviral therapy, including anti- non-structural-5A, and to characterize the preexisting resistance-associated substitutions in subjects treated with anti- non-structural-5A inhibitors...
July 21, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28727946/confounding-by-single-nucleotide-polymorphism-rs117648444-p70s-affects-the-association-of-interferon-lambda-locus-variants-with-response-to-interferon-%C3%AE-ribavirin-therapy-in-patients-with-chronic-genotype-3-hepatitis-c-virus-infection
#3
Anand Bhushan, Sumona Ghosh, Samsiddhi Bhattacharjee, Sreedhar Chinnaswamy
Genome-wide association studies discovered interferon lambda (IFNL or IFN-λ) locus on chromosome 19 to be involved in clearance of chronic hepatitis C virus (HCV) infection in patients following interferon-α-ribavirin (IFN-RBV) therapy. Subsequent studies established a dinucleotide polymorphism rs368234815, as the prime causal variant behind this association. The ΔG allele of this variant gives rise to a new IFNL gene, IFNL4, coding for IFN-λ4 whose activity paradoxically associates with lesser viral clearance rates...
July 20, 2017: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/28727051/carotenoid-intake-and-scd-genotype-exert-complementary-effects-over-fat-content-and-fatty-acid-composition-in-duroc-pigs
#4
E Henriquez-Rodriguez, R N Pena, A R Seradj, L Fraile, P Christou, M Tor, J Estany
Nutritional and genetic strategies are needed to enhance intramuscular fat (IMF) and MUFA content without altering carcass leanness. Dietary vitamin A restriction has been suggested to specifically promote IMF, whereas a polymorphism of the () gene has shown to specifically increase MUFA. The purpose of this study was to investigate the combined effects of provitamin A (PVA) carotenoid intake and genotype (>) on hepatic retinoid content and on the liver, muscle (LM and gluteus medius [GM]), and subcutaneous fat (SF) content and fatty acid composition...
June 2017: Journal of Animal Science
https://www.readbyqxmd.com/read/28724048/impact-of-alcohol-consumption-among-patients-in-hepatitis-c-virus-treatment
#5
Andréa Carvalho Maia Vieira-Castro, Luiz Carlos Marques de Oliveira
BACKGROUND: Recent studies have questioned the recommendation of abstinence from alcohol for at least 6 months for alcoholic patients to be treated for hepatitis C. OBJECTIVE: The present study aimed to assess the impact of alcohol consumption among patients undergoing hepatitis C treatment. METHODS: In this cross-sectional study, 121 patients [78 (64.5%) men; 28-70 years] were evaluated. They were divided as follows: patients who consumed <12 g of ethanol/day throughout life (Group 1), 12-59 g/day (Group 2) and ≥60 g/day (Group 3)...
July 13, 2017: Arquivos de Gastroenterologia
https://www.readbyqxmd.com/read/28713830/the-prevalence-and-replication-capacity-of-a-tibetan-dominant-hbv-strain-c-d-recombinant
#6
Lingyao Du, Menghan Liu, Miao Liu, Taoyou Zhou, Xing Cheng, Cong Liu, Hong Tang
This study aimed to estimate the distribution of hepatitis B virus (HBV) C/D recombinant in Han and Tibet patients with chronic hepatitis B (CHB) and then learn such strain's replication capacity in vivo. A total of 331 serum samples were collected from Han outpatients from Sichuan Province and Tibetan outpatients from Tibet. Viral genotypes in these samples were identified. An HBV replicative plasmid of C/D recombinant was constructed with selected genome. Sequentially, HBV replicative mouse models were established and the replication capacity of the viral strain was studied in vivo...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28710853/real-world-effectiveness-of-sofosbuvir-based-treatment-regimens-for-chronic-hepatitis-c-genotype-3-infection-results-from-the-multicenter-german-hepatitis-c-cohort-gecco-03
#7
Malte H Wehmeyer, Patrick Ingiliz, Stefan Christensen, Dietrich Hueppe, Thomas Lutz, Karl Georg Simon, Knud Schewe, Christoph Boesecke, Axel Baumgarten, Heiner Busch, Juergen Rockstroh, Guenther Schmutz, Torben Kimhofer, Florian Berger, Stefan Mauss, Julian Schulze Zur Wiesch
There are limited data regarding the real world effectiveness of direct acting antivirals (DAA) for the therapy of chronic genotype 3 hepatitis C virus (HCV) infection. All HCV genotype 3 infected patients from the German hepatitis C cohort (GECCO), which is a prospective database of nine German hepatitis C treatment centers, were included in the study. 342 chronically infected HCV genotype 3 patients were analyzed (253 males [74.0%], mean age 47.3 years, 127 cirrhotic patients [37.1%] mostly with Child A cirrhosis, 113 treatment experienced patients [37...
July 15, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/28710798/can-quantitative-hepatitis-b-surface-antigen-levels-predict-the-severity-of-liver-disease-in-genotype-e-patients
#8
Gayatri Chakrabarty, Matthew Bruce, Mary Horner, Bo Wang, Kosh Agarwal, Ivana Carey
The utility of quantitative Hepatitis B surface antigen (qHBsAg) level as a marker of chronic hepatitis B (CHB)-related liver damage is not fully delineated, but is becoming increasingly relevant. Quantitative HBsAg levels are linked with progression of liver disease in HBeAg-negative genotype B and C patients, but it is not clear whether this is consistent across all HBV genotypes. In this single-center, cross-sectional observational study, we evaluated whether qHBsAg levels can predict the severity of liver disease in genotype E patients...
July 14, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28707600/a-new-potent-ns5a-inhibitor-in-the-management-of-hepatitis-c-virus-ravidasvir
#9
Enas Hafez, Tamer Elbaz, Mohamed El Kassas, Gamal Esmat
Background: Chronic hepatitis C virus (HCV) is a worldwide health problem that can lead to liver cirrhosis, liver cell failure and numerous subsequent complications such as hepatocellular carcinoma. Till the near past, pegylated interferon was the standard of care therapy. However, it was associated with suboptimal success rates and many side effects. Thereafter, direct antiviral agents (DAA) appeared and played the key role in management of HCV. One of those recent DAA is ravidasvir. Summary: It is a potent NS5A inhibitor that was formerly known as PPI-668...
July 13, 2017: Current Drug Discovery Technologies
https://www.readbyqxmd.com/read/28704535/interferon-related-genetic-markers-of-necroinflammatory-activity-in-chronic-hepatitis-c
#10
Rosario López-Rodríguez, Ángel Hernández-Bartolomé, María Jesús Borque, Yolanda Rodríguez-Muñoz, Samuel Martín-Vílchez, Luisa García-Buey, Leticia González-Moreno, Yolanda Real-Martínez, Paloma Muñoz de Rueda, Javier Salmerón, José Ramón Vidal-Castiñeira, Carlos López-Larrea, Luis Rodrigo, Ricardo Moreno-Otero, Paloma Sanz-Cameno
INTRODUCTION: Chronic hepatitis C (CHC) is a major cause of liver disease worldwide which often leads to progressive liver inflammation, fibrosis, cirrhosis and hepatocellular carcinoma (HCC). CHC displays heterogeneous progression depending on a broad set of factors, some of them intrinsic to each individual such as the patient's genetic profile. This study aims to evaluate the contribution of certain genetic variants of crucial interferon alpha and lambda signaling pathways to the hepatic necroinflammatory activity (NIA) grade of CHC patients...
2017: PloS One
https://www.readbyqxmd.com/read/28704381/sofosbuvir-based-treatment-of-chronic-hepatitis-c-genotype-3-infections-a-scandinavian-real-life-study
#11
Olav Dalgard, Ola Weiland, Geir Noraberg, Lars Karlsen, Lars Heggelund, Martti Färkkilâ, Ulla Balslev, Erika Belard, Anne Øvrehus, Mette Skalshøi Kjær, Henrik Krarup, Birgit Thorup Røge, Sofie Hallager, Lone G Madsen, Alex Lund Laursen, Martin Lagging, Nina Weis
BACKGROUND AND AIMS: Chronic hepatitis C virus (HCV) genotype 3 infection with advanced liver disease has emerged as the most challenging to treat. We retrospectively assessed the treatment outcome of sofosbuvir (SOF) based regimes for treatment of HCV genotype 3 infections in a real life setting in Scandinavia. METHODS: Consecutive patients with chronic HCV genotype 3 infection were enrolled at 16 treatment centers in Denmark, Sweden, Norway and Finland. Patients who had received a SOF containing regimen were included...
2017: PloS One
https://www.readbyqxmd.com/read/28703905/successful-treatment-of-chronic-hepatitis-c-infection-with-directly-acting-antivirals-in-renal-transplant-recipients
#12
Sunil Taneja, Ajay Duseja, Arka De, Vivek Kumar, Raja Ramachandran, Ashish Sharma, Radha K Dhiman, Krishan L Gupta, Yogesh Chawla
AIMS: The data regarding the treatment of chronic hepatitis C (CHC) in renal transplant recipients is lacking from the Asia-Pacific region. Aim of the present study was to assess the safety and efficacy of directly acting antivirals (DAAs) in the treatment of CHC infection in renal transplant recipients. METHODS: A total of 47 CHC infected renal transplant recipients were enrolled in this real life observational cohort analysis between March 2015 and September 2016...
July 13, 2017: Nephrology
https://www.readbyqxmd.com/read/28703131/egfr-rs11506105-and-ifnl3-snps-but-not-rs8099917-are-strongly-associated-with-treatment-responses-in-iranian-patients-with-chronic-hepatitis-c
#13
M Asnavandi, M Zargar, F Vaziri, F R Jamnani, S Gharibzadeh, A Fateh, S D Siadat
Interferon lambda 3 (IFNL3) and epidermal growth factor receptor (EGFR) single nucleotide polymorphisms (SNPs) may play a key role in the spontaneous clearance of hepatitis C virus (HCV) and treatment responses. The aim of this study was to evaluate the effect of IFNL3 SNPs and EGFR rs11506105 on treatment outcomes in patients with chronic HCV (CHC). IFNL3 SNPs and EGFR rs11506105 were genotyped by PCR-restriction fragment length polymorphism and PCR-sequencing, respectively, in 235 naïve patients with CHC infection...
July 13, 2017: Genes and Immunity
https://www.readbyqxmd.com/read/28699869/hepatitis-c-virus-in-vitro-replication-is-efficiently-inhibited-by-acridone-fac4
#14
Guilherme Rodrigues Fernandes Campos, Cíntia Bittar, Ana Carolina Gomes Jardim, Jacqueline Farinha Shimizu, Mariana Nogueira Batista, Eder Ramos Paganini, Letícia Ribeiro de Assis, Christopher Bartlett, Mark Harris, Vanderlan da Silva Bolzani, Luis Octavio Regasini, Paula Rahal
Hepatitis C virus (HCV) affects about 170 million people worldwide. The current treatment has a high cost and variable response rates according to the virus genotype. Acridones, a group of compounds extracted from natural sources, showed potential antiviral actions against HCV. Thus, this study aimed to evaluate the effect of a panel of 14 synthetic acridones on the HCV life cycle. The compounds were screened using an Huh7.5 cell line stably harbouring the HCV genotype 2a subgenomic replicon SGR-Feo-JFH-1...
July 12, 2017: Journal of General Virology
https://www.readbyqxmd.com/read/28696069/hcc-associated-single-nucleotide-variants-and-deletions-identified-using-genome-wide-high-throughput-analysis-of-hbv
#15
Wen-Chun Liu, I-Chin Wu, Yen-Chien Lee, Chih-Peng Lin, Ji-Hong Cheng, Yih-Jyh Lin, Chia-Jui Yen, Pin-Nan Cheng, Pei-Fu Li, Yi-Ting Cheng, Pei-Wen Cheng, Koun-Tem Sun, Shu-Ling Yan, Jia-Jhen Lin, Jui-Chu Yang, Kung-Chao Chang, Cheng-Hsun Ho, Vincent S Tseng, Bill Chia-Han Chang, Jaw-Ching Wu, Ting-Tsung Chang
This study investigated hepatitis B virus (HBV) single nucleotide variants (SNVs) and deletion mutations linked with hepatocellular carcinoma (HCC). Ninety-three HCC patients and 108 non-HCC patients were enrolled for HBV genome-wide next-generation sequencing (NGS) analysis. Systemic literature review and meta-analysis were performed to validate NGS-defined HCC-associated SNVs and deletions. The experimental results identified 60 NGS-defined HCC-associated SNVs, including 41 novel SNVs, and their pathogenic frequencies...
July 11, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28694000/boceprevir-based-triple-therapy-to-rescue-hcv-genotype-1-hbv-dually-infected-patients-refractory-to-peginterferon-plus-ribavirin-combination-therapy-in-taiwan
#16
Meng-Hsuan Hsieh, Ming-Lun Yeh, Tung-Hung Su, Ta-Wei Liu, Chuang-Feng Huang, Ching-I Huang, Shu-Chi Wang, Jee-Fu Huang, Chia-Yen Dai, Jia-Horng Kao, Wan-Long Chuang, Pei-Jer Chen, Chun-Jen Liu, Ming-Lung Yu
BACKGROUND/PURPOSE: The role of directly-acting antivirals (DAA)-containing regimens in the treatment of patients dually-infected with hepatitis C virus (HCV) and hepatitis B virus (HBV) remains unclear. The pilot study aimed to explore the safety and efficacy of a protease inhibitor, boceprevir, in combination with peginterferon/ribavirin for HCV genotype 1 (HCV-1)/HBV dually-infected patients refractory to prior peginterferon/ribavirin. METHODS: Twelve peginterferon-experienced patients dually-infected with HCV-1/HBV were assigned to receive boceprevir 800 mg, twice a day, plus peginterferon-α 2b 1...
July 7, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/28692890/porcine-blood-used-as-ingredient-in-meat-productions-may-serve-as-a-vehicle-for-hepatitis-e-virus-transmission
#17
Ingeborg L A Boxman, Claudia C C Jansen, Geke Hägele, Ans Zwartkruis-Nahuis, Jeroen Cremer, Harry Vennema, Aloys S L Tijsma
The aim of the present study was to investigate whether the use of porcine blood(products) in food could be a risk for a hepatitis E virus (HEV) infection. HEV RNA was detected in 33/36 batches of (non-heated) liquid products and in 7/24 spray dried powder products. Contamination levels varied among the products, but were highest in liquid whole blood, plasma and fibrinogen reaching levels of 2.2×10(2) to 2.8×10(2) HEV genome copies per 0.2g. Sequence analyses revealed genotype 3 strains, of which two were 100% (493nt) identical to recently diagnosed HEV cases, although no direct epidemiological link was established...
June 28, 2017: International Journal of Food Microbiology
https://www.readbyqxmd.com/read/28692182/gsk2878175-a-pan-genotypic-non-nucleoside-ns5b-polymerase-inhibitor-in-healthy-and-treatment-na%C3%A3-ve-chronic-hepatitis-c-subjects
#18
Stephen D Gardner, Joseph Kim, Sharon Baptiste-Brown, Vincent Lopez, Robert Hamatake, Jianjun Gan, Stephen Edwards, Lucinda Elko-Simms, Etienne F Dumont, Martin Leivers, Zhi Hong, Melanie T Paff
GSK2878175 is a potent, pan-genotypic, non-nucleoside, non-structural protein 5B palm polymerase inhibitor being developed for the treatment of chronic hepatitis C (CHC). A first-in-human, randomized, placebo-controlled, dose escalation study, evaluated the safety and pharmacokinetics of GSK2878175 administered as single and repeat oral doses (once daily for 14 days) to healthy volunteers. A separate proof-of-concept, placebo-controlled, repeat dose (once daily for 2 days) study evaluated the safety, pharmacokinetics, and antiviral activity of GSK2878175 monotherapy in treatment naïve, non-cirrhotic, subjects with HCV genotype 1 [1a and 1b], 2, or 3...
July 10, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28691377/effectiveness-of-8-or-12-weeks-of-ledipasvir-and-sofosbuvir-in-real-world-treatment-na%C3%A3-ve-genotype-1-hepatitis-c-infected-patients
#19
M P Curry, E B Tapper, B Bacon, D Dieterich, S L Flamm, L Guest, K V Kowdley, Y Lee, S Milligan, N Tsai, Z Younossi, N H Afdhal
BACKGROUND: Treatment of genotype 1 hepatitis C virus (HCV) infection with combination direct acting anti-virals is associated with very high rates of sustained virological response (SVR). Daily combination of ledipasvir and sofosbuvir for 12 weeks is approved for the treatment of genotype 1 HCV patients, though noncirrhotic patients who are naïve to treatment with a baseline HCV RNA <6 million IU/mL can be treated for 8 weeks. This guidance stemmed from a post hoc analysis of the ION 3 clinical trial, which demonstrated similar SVR for patients treated with ledipasvir and sofosbuvir with or without ribavirin for 8 or 12 weeks...
July 10, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28687901/virological-and-clinical-characteristics-of-hepatitis-b-virus-genotype-a
#20
REVIEW
Kiyoaki Ito, Masashi Yoneda, Kazumasa Sakamoto, Masashi Mizokami
Hepatitis B virus (HBV) infection is one of the most prevalent chronic viral infections in humans. The overall prevalence of hepatitis B surface antigen (HBsAg) is reported to be 3.6%; however, it varies depending upon the geographic area. HBV is classified into ten genotypes (A through J) on the basis of an intergroup genomic divergence of > 8%. Specifically, HBV genotype A exhibits several unique virological and clinical characteristics and can be further classified into seven subtypes. Among them, subtype A2 or Ae (A2/[e]) is occasionally responsible for nosocomial infection and among homosexual males...
July 7, 2017: Journal of Gastroenterology
keyword
keyword
85439
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"